11 Einträge gefunden

1. Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANT

   1. Engler, Tobias
   2. Fasching, Peter A
   3. Lüftner, Diana
   4. Hartkopf, Andreas D
   5. Müller, Volkmar
   6. Kolberg, Hans-Christian
   7. Hadji, Peyman

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry

   1. Müller, Volkmar
   2. Hein, Alexander
   3. Hartkopf, Andreas D
   4. Fasching, Peter A
   5. Kolberg, Hans-Christian
   6. Hadji, Peyman
   7. Tesch, Hans

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status

   1. Hein, Alexander
   2. Hartkopf, Andreas D
   3. Emons, Julius
   4. Lux, Michael P
   5. Volz, Bernhard
   6. Taran, Florin-Andrei
   7. Overkamp, Friedrich

   2021 - Forschungsinformationssystem des UKE
4. Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine

   1. Laakmann, Elena
   2. Emons, Julius
   3. Taran, Florin-Andrei
   4. Janni, Wolfgang
   5. Uhrig, Sabrina
   6. Overkamp, Friedrich
   7. Kolberg, Hans-Christian

   2020 - Forschungsinformationssystem des UKE
5. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

   1. Huebner, Hanna
   2. Kurbacher, Christian M
   3. Kuesters, Geoffrey
   4. Hartkopf, Andreas D
   5. Lux, Michael P
   6. Huober, Jens
   7. Volz, Bernhard

   2020 - Forschungsinformationssystem des UKE
6. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab

   1. Michel, Laura L
   2. Hartkopf, Andreas D
   3. Fasching, Peter A
   4. Kolberg, Hans-Christian
   5. Hadji, Peyman
   6. Tesch, Hans
   7. Häberle, Lothar

   2020 - Forschungsinformationssystem des UKE
7. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry

   1. Müller, Volkmar
   2. Nabieva, Naiba
   3. Häberle, Lothar
   4. Taran, Florin-Andrei
   5. Hartkopf, Andreas D
   6. Volz, Bernhard
   7. Overkamp, Friedrich

   2018 - Forschungsinformationssystem des UKE
8. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry

   1. Lux, Michael P
   2. Nabieva, Naiba
   3. Hartkopf, Andreas D
   4. Huober, Jens
   5. Volz, Bernhard
   6. Taran, Florin-Andrei
   7. Overkamp, Friedrich

   2018 - Forschungsinformationssystem des UKE - frei zugänglich
9. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry

   1. Hartkopf, Andreas D
   2. Huober, Jens
   3. Volz, Bernhard
   4. Nabieva, Naiba
   5. Taran, Florin-Andrei
   6. Schwitulla, Judith
   7. Overkamp, Friedrich

   2018 - Forschungsinformationssystem des UKE
10. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial

    1. Jueckstock, Julia
    2. Rack, Brigitte
    3. Friedl, Thomas W P
    4. Scholz, Christoph
    5. Steidl, Julia
    6. Trapp, Elisabeth
    7. Tesch, Hans

    2016 - Forschungsinformationssystem des UKE - frei zugänglich
11. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study

    1. Hein, Alexander
    2. Lambrechts, Diether
    3. von Minckwitz, Gunter
    4. Häberle, Lothar
    5. Eidtmann, Holger
    6. Tesch, Hans
    7. Untch, Michael

    2015 - Forschungsinformationssystem des UKE